P eripheral arterial disease (PAD) is a complication of systemic atherosclerosis that affects >10 million people in the United States alone, where occlusions reduce perfusion to the leg(s) causing pain with walking, pain at rest, and ischemic ulcers that put the limb at risk for amputation.
1,2 Surgical and catheter-based revascularization therapies are preferred first line of treatment for patients with the most extreme form of PAD, but many patients are poor candidates or have no revascularization option.
1,2 Thus, ≈200 000 amputations/yr occur in the United States alone, with PAD being the major cause, and no medical therapies are available to increase leg perfusion. 3 In symptomatic PAD patients, a total occlusion in the inflow vessels means that resting or maximal leg blood flow is dependent on the extent of the angiogenic response to ischemia. 4 Vascular endothelial growth factor-A (VEGF-A) is a key member in the VEGF superfamily that can bind and activate vascular endothelial growth factor receptor (VEGFR)1 and VEGFR2, to modulate physiological and pathological angiogenesis. 5 VEGF-A-mediated VEGFR2-signaling activation is largely viewed as the dominant receptor tyrosine kinase signaling to induce angiogenesis. 6, 7 VEGFR1 plays important roles in several cardiovascular diseases including experimental PAD [8] [9] [10] ; however, the processes that regulate VEGFR1 activation or VEGFR1-specific downstream signaling events are not clear.
Human clinical trials aimed at inducing VEGF-Amediated VEGFR2 signaling in PAD via VEGF-A delivery to ischemic muscle were not successful. [11] [12] [13] Many factors may have contributed for this lack of beneficial effect, but it is clear that induction of functional blood vessel formation in ischemic muscle is a formidable challenge, and an inadequate understanding of VEGF-VEGFR signaling is one major possible explanation. Our understanding of the VEGF ligands has become more complex with the recognition of antiangiogenic VEGF-A isoforms family, termed VEGF xxx b (VEGF 165 b), which occurs from alternate splicing in exon-8 of VEGF-A (a 6 amino acid frame shift from CDKPRR [proangiogenic] to PLTGKD [antiangiogenic] ). 14, 15 Replacement of positively charged arginine residues in proangiogenic isoforms with neutral aspartic acid and lysine in antiangiogenic isoforms is predicted to decrease VEGFR2 activation 16 and angiogenesis. On the basis of the existing paradigm on VEGF 165 b-VEGFR2 interactions, it was predicted that VEGF 165 b inhibition would increase the bioavailability of proangiogenic VEGF-A isoforms to VEGFR2 for receptor-mediated angiogenesis. However, our data will show that VEGF 165 b modulates VEGFR1 and a novel VEGFR1 signal transducer and activator of transcription (STAT3) signaling pathway that promotes angiogenesis and perfusion recovery in PAD.
Methods
Please see the Materials and Methods section in the Online Data Supplement.
Results

In Human and Experimental PAD Muscle, VEGF 165 b Induction Occurs With Ischemia and Is Associated With Lower VEGFR1, Not VEGFR2 Activation
In a previous study of gastrocnemius skeletal muscle from PAD and non-PAD control subjects (age and sex matched), we reported that VEGF 165 b was higher in PAD muscle using an ELISA. 14 Kikuchi et al 17 more recently showed that peripheral blood monocytes from PAD versus control patients express significantly higher VEGF 165 b by immunoblotting. 17 We first confirmed that VEGF-A antibody, raised against full-length VEGF-A protein, detects both proangiogenic (VEGF 165 a) and antiangiogenic (VEGF 165 b) VEGF-A isoforms, and an isoform-specific VEGF xxx b antibody raised against the 6 amino acids of exon8b in VEGF xxx b isoforms is extremely specific to recombinant VEGF 165 b and does not detect recombinant VEGF 165 a (Online Figure IA) , which was in accordance to previous publications. 15, 18 In cell-free ELISA, although VEGF-A was able to detect both recombinant VEGF 165 a and VEGF 165 b isoforms (at equal concentrations) with similar affinity, VEGF 165 What Is Known?
• Alternate splicing in exon-8 of vascular endothelial growth factor (VEGF)-A gene produces 2 isoform families that are typically described as proangiogenic (C-terminal amino acid sequence CDKPRR) and antiangiogenic (C-terminal amino acid sequence SLTRKD).
• The antiangiogenic VEGF-A isoforms were predicted to inhibit proangiogenic VEGF-A isoforms' ability to activate VEGFR2.
What New Information Does This Article Contribute?
• Decreasing the antiangiogenic VEGF-A levels increased VEGFR1 activation with no change in VEGFR2 activation in experimental peripheral arterial disease (PAD).
• Increasing the antiangiogenic VEGF-A isoform decreased VEGFR1 activation and increased VEGFR2 activation.
• Inhibition of antiangiogenic VEGF-A isoforms increased VEGFR1-STAT3 binding interactions to enhance STAT3 activation that was independent of Janus-activated kinase-1/Janus-activated kinase-2 activation.
The antiangiogenic VEGF-A isoforms exist in human muscle, but how these antiangiogenic VEGF-A isoforms modulate ischemic muscle recovery in PAD is not clear. In human and experimental PAD, increased levels and binding of antiangiogenic VEGF-A isoforms to VEGFR1 correlated with decreased VEGFR1 activation. Inhibition of antiangiogenic VEGF-A isoforms in preclinical PAD models increased binding of proangiogenic VEGF-A to VEGFR1 to increase VEGFR1-STAT3 interactions and signaling resulting in enhanced ischemic muscle perfusion. VEGFR2 activation is necessary to revascularize ischemic muscle, and the antiangiogenic VEGF-A isoforms were predicted to inhibit VEGFR2. Our work alters current thinking about VEGFR-mediated angiogenesis by showing that antiangiogenic VEGF-A isoforms are inhibitors/ blockers for VEGFR1 (not VEGFR2) and that removal of the inhibitor increased VEGFR1 activation to improve ischemic muscle perfusion. Our data provide the first evidence that strategies designed to inhibit the antiangiogenic isoforms activate VEGFR1-STAT3 signaling. Furthermore, our finding that the antiangiogenic VEGF-A isoforms can inhibit proangiogenic VEGF-A isoforms even at 10× lower levels may also explain the failure of previous human trials designed to increase the proangiogenic VEGF-A in ischemic muscle. Hence, therapies aimed at inhibiting antiangiogenic VEGF-A isoforms may indeed provide a better strategy to promote perfusion in PAD through VEGFR1 and not through VEGFR2 activation.
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VEGF 165 a even at 20× higher concentration than VEGF 165 b (data not shown), indicating that VEGF 165 b antibody is highly specific for VEGF xxx b isoforms and hence was used to examine VEGF 165 b levels and function in our experiments. We next quantified total VEGF-A and VEGF 165 b levels in PAD and normal muscle biopsies by ELISA. In PAD muscle biopsies, we observed a decrease in total VEGF-A levels (normal: 166.3±27.8 versus PAD: 135.6±5.5 pg/mg; Figure 1A , left), with an increase in the VEGF xxx b fraction (normal: 81.6±9.5 versus PAD: 98.1±12.7 pg/mg; Figure 1A , middle) compared with normal muscle biopsies. Subtracting VEGF xxx b fraction from total VEGF-A showed that the VEGF xxx a fraction was significantly reduced (≈2×; P=0.04) in PAD muscle biopsies compared with normal (normal: 84.7±21.6 versus PAD: 37.5±8.0 pg/mg; Figure 1A , right). We confirmed the specificity of our VEGF-A and VEGF xxx b ELISA data from PAD and normal muscle biopsies by immunoblot analysis of VEGF-A and VEGF 165 b. In immunoblot analysis, although no significant differences were observed in total VEGF-A levels between PAD and normal muscle biopsies, VEGF 165 b levels were significantly induced (P<0.03) in PAD muscle biopsies compared with normal (Online Figure IB) . Because VEGF 165 b antibody detects only VEGF 165 b and the VEGF-A antibody detects both pro-and antiangiogenic isoforms, we derived a ratio of VEGF 165 b:VEGF-A, which showed that VEGF 165 b is induced ≈3X in PAD muscle versus normal (Online Figure IB) embryonic lethality in VEGFR2 global knockout mice, 21 indicating a critical role for Y1175 in regulating VEGFR2 downstream signaling. Hence, we focused on examining the status of VEGFR2-Y1175 activation in our experiments. Immunoblot of the VEGFR2-immunoprecipitated fraction showed significantly higher VEGFR2 activation (Y1175) in the PAD muscle biopsies versus control (P=0.009; Figure 1B ). To examine whether increased VEGFR2 phosphorylation correlates with changes in binding of VEGF-A and VEGF 165 b to VEGFR2, we used the same VEGFR2-immunoprecipitated samples from normal and PAD muscle biopsies and analyzed for VEGF 165 b and total VEGF-A. Despite lower total VEGF-A (VEGF 165 a) and higher VEGF 165 b levels in PAD versus normal muscle biopsies, no significant differences in VEGF 165 b or total VEGF-A binding was observed in VEGFR2-immunoprecipitated complexes between PAD and normal muscle biopsies ( Figure 1B) , suggesting that higher VEGF 165 b levels in PAD versus normal do not inhibit VEGFR2 activation.
Using a similar strategy and the same cohort, we next examined the degree of VEGFR1 activation in human PAD versus control. Immunoblot of VEGFR1-immunoprecipitated fraction showed significantly decreased VEGFR1 activation (Y1333) in PAD muscle biopsies versus normal (P=0.003; Figure 1C ). To examine whether decreased VEGFR1-phosphorylation correlates with changes in binding of VEGF-A and VEGF 165 b to VEGFR1, we used the same VEGFR1-immunoprecipitated samples and analyzed for bound VEGF 165 b and total VEGF-A. VEGFR1 pull-down experiments from PAD and normal muscle biopsies showed a significant increase in VEGF 165 b levels bound to VEGFR1 with no significant change in total VEGF-A in PAD muscle biopsies compared with normal (P<0.03; Figure 1C ). Thus, VEGFR1 activation inversely correlated with increased VEGF 165 b binding to VEGFR1.
We then used unilateral femoral artery ligation and resection (hindlimb ischemia [HLI] ) in Balb/c mice, as a preclinical experimental model for severe PAD (critical limb ischemia PAD). [22] [23] [24] [25] [26] To determine whether VEGF 165 b induction correlates with decreased activation of VEGFR1 versus VEGFR2 in ischemic muscle compared with nonischemic muscle, we analyzed cells from nonischemic and ischemic whole muscle tissue by flow cytometry (see Online Figure II To determine whether changes in VEGFR1 activation are because of the receptor-bound VEGF 165 b in experimental PAD, we performed VEGFR1 pull-down experiments and immunoblotted for VEGF 165 b and VEGF-A. Although there was no significant difference in total VEGF-A bound to VEGFR1 between NGA and IGA, we observed a significant increase in VEGF 165 b bound to VEGFR1-immunoprecipitated fractions (P<0.04; Figure 2H ) in ischemic muscle compared with nonischemic muscle. These data demonstrated that with ischemia, there is increased production and binding of VEGF 165 b to VEGFR1 with decreased VEGFR1 activation in ischemic muscle compared with nonischemic muscle in experimental PAD.
We next examined the role of VEGF 165 b in modulating outcomes in experimental PAD by inhibiting VEGF 165 b in ischemic muscle. Consistent with the previous findings from Kikuchi et al, 17 
VEGF 165 b Inhibition Does Not Activate the Classical Proangiogenic VEGFR2 Signaling but Activates VEGFR1 to Promote Angiogenesis and Perfusion Recovery in Ischemic Muscle
On the basis of the well-established role of VEGFR2 signaling in angiogenesis, we first examined whether increased angiogenesis and perfusion post VEGF 165 b inhibition is because of the activation of VEGFR2 signaling in ischemic muscle treated with VEGF 165 b antibody compared with IgG. Immunoblotting of VEGFR2 and its key signaling intermediates 7, 19 showed no significant differences in VEGFR2 activation (pVEGFR2 Y1175 / VEGFR2; Figure 3A ) or activation of VEGFR2 downstream signaling including Akt, Erk, or eNos (data not shown) in VEGF 165 b antibody-treated ischemic muscle compared with IgG-treated ischemic muscle, suggesting that VEGF 165 b inhibition did not activate VEGFR2 signaling in ischemic muscle.
Thus, we next examined the status of VEGFR1 activation post VEGF 165 b inhibition in ischemic muscle. Immunoblotting showed that VEGF 165 b antibody treatment significantly induced VEGFR1 activation by increasing Y1333 phosphorylation compared with IgG treatment in ischemic muscle (≈3×; Figure 3B ). VEGFR1 activation in ischemic muscle ECs post VEGF 165 b inhibition was confirmed visually by performing double immunofluorescence analysis for pVEGFR1 Y1333 (AlexaFluor555) and CD31(AlexaFluor488; Figure 3C ). The extent of endothelium-specific VEGFR1 activation was quantified by flow cytometry in ischemic muscle treated with VEGF 165 b antibody or IgG. Flow cytometry showed a significant increase in VEGFR1 Y1333 activation in ischemic endothelium treated with VEGF 165 b antibody compared with IgG (P=0.0003; Figure 3D ).
We next examined whether VEGF 165 b inhibition can induce endothelium-specific VEGFR1 activation in vitro. Figure IV) . Our data demonstrating that VEGF 165 b inhibition activates VEGFR1 but not VEGFR2 in ischemic muscle to induce a proangiogenic phenotype clearly suggest that VEGFR1 activation also plays a major role in modulating angiogenesis and perfusion recovery in experimental critical limb ischemia PAD.
To confirm that VEGFR1 plays a role in regulating angiogenesis post VEGF 165 to or higher than VEGF 165 a and VEGF 165 b individual treatments ( Figure 4D ). These data show that although VEGF 165 b functions as an agonist for VEGFR2, it is a competitive inhibitor for VEGF 165 a-meditated VEGFR1 activation.
To obtain a direct correlation between VEGF 165 b and VEGFR1 activation in vivo, we next induced VEGF 165 b levels in Balb/c normal skeletal muscle in the hind limbs by electroporation and examined the extent of endotheliumspecific VEGFR1 activation by flow cytometry. We found that gastrocnemius muscle that received VEGF 165 b-expressing plasmid showed a significant increase in VEGF 165 b levels (P=0.003; Figure 4C ) correlating with decreased endothelial (CD31 + CD45 − ) VEGFR1 activation compared with gastrocnemius muscle that received scrambled plasmid (P<0.05; Figure 4D ). However, no changes in endothelium-specific VEGFR2 activation were observed in skeletal muscle that received VEGF 165 b-expressing plasmid compared with scrambled plasmid ( Figure 4E ). These data showed that increased VEGF 165 b levels could decrease VEGFR1 activation independent of the ischemic state of tissue.
Although extensive data exist on VEGFR2 signaling in angiogenesis, information on VEGFR1 signaling is extremely sparse. On the basis of the previous reports demonstrating that ischemic myocardium from VEGFR1 +/− mice had lesser STAT3 binding to DNA than VEGFR1 +/+ mice 29 and that VEGFR1 associated with STAT3 in cancer models, 30, 31 we examined the status of STAT3 activation post VEGF 165 
VEGF 165 b Inhibition Induces VEGFR1-STAT3 Interactions to Promote STAT3 Activation in Ischemic Muscle
As shown in Figure 3D and Online Figure IV , STAT3 activation post VEGF 165 b inhibition occurred without changes in Jak1/Jak2 activation, and a recent report showed that VEGFR1 is physically associated with STAT3 in cancer models. 30, 31 Hence, we sought to determine whether VEGFR1 could bind and activate STAT3 on VEGF 165 b inhibition. In vivo, VEGFR1 was immunoprecipitated from VEGF 165 b antibody-treated and IgG-treated ischemic muscle samples and examined for physical interactions between VEGFR1 and STAT3. In VEGFR1-immunoprecipitated fractions, immunoblotting of STAT3 showed significantly higher STAT3 binding (≈2×; P<0.03) after VEGF 165 b inhibition than that after IgG inhibition ( Figure 5F ). In vitro, immunoblotting of VEGFR1-immunoprecipitated complexes from VEGF 165 b antibody-treated HUVECs showed no significant changes in endothelial STAT3 binding compared with IgG-treated HUVECs under normal conditions (Online Figure IXB) . However, VEGFR1-immunoprecipitated complexes from HSS HUVECs (P=0.0002; Figure 5G ) treated with VEGF 165 b antibody showed a significant increase in STAT3 binding to VEGFR1 compared with those treated with IgG.
Activation of VEGFR1-STAT3 signaling in ischemic muscle post VEGF 165 b inhibition was visually confirmed by double immunofluorescence analysis of pVEGFR1 Y1333 (AlexaFluor-555) and pSTAT3 (AlexaFluor-488), which showed extensive colocalization of pVEGFR1 and pSTAT3 ( Figure 5H ). Flow cytometry of CD31 + CD45
− ECs showed that VEGF 165 b inhibition induced a significant increase in the numbers of pVEGFR1 + pSTAT3 + ECs (IgG: 2.1±0.8% versus VEGF 165 b antibody: 5.0±0.8%; P<0.02; Figure 5I ) in ischemic muscle compared with IgG.
To confirm that VEGFR1 has the ability to activate STAT3, HEK293 cells (deficient in VEGFR1 and VEGFR2) were transfected with a VEGFR1-expressing plasmid (Online Figure X) and assayed for STAT3 activation. Immunoblotting showed that VEGFR1 expression in HEK293 significantly January 20, 2017 Figure 5L ), indicating that VEGFR1 can directly enhance STAT3 activation.
To understand the causal role of VEGFR1 in regulating STAT3 activation in ischemic muscle, we developed VEGFR1 +/− mice on Balb/c background (VEGFR1 −/− are embryonic lethal), which enabled us not only to understand the role of VEGFR1 in regulating STAT3 activation but also to further confirm the causal role of VEGFR1 in promoting perfusion recovery post VEGF 165 b inhibition. Quantitative polymerase chain reaction and VEGFR1 immunofluorescence analysis showed that VEGFR1 +/− mice have comparable VEGFR1 levels in normal skeletal muscle, but these mice cannot upregulate VEGFR1 in ischemic muscle compared with wild-type (WT) littermates ( Figure 6A and 6B) . +/− IGA. These data clearly indicated that VEGFR1 has the ability to regulate STAT3 activation in ischemic muscle.
Discussion
Our knowledge of the VEGF superfamily continues to increase. Although the totality of data to date have led to the conclusion that VEGF 165 b antagonizes VEGF 165 a to decrease VEGFR2 activation, our study demonstrates that VEGF 165 b does not inhibit VEGFR2 in endothelial cells and depletion/ displacement of VEGF 165 b in ischemic muscle did not result in more VEGFR2 activation. Rather, we found an increased bioavailability of VEGF 165 a to bind and activate VEGFR1. Furthermore, VEGF 165 b inhibition increased VEGFR1-STAT3 interactions to promote angiogenesis and enhance perfusion recovery. Our study demonstrates, for the first time, that VEGF 165 b inhibits VEGFR1 signaling in ischemic muscle and depletion of VEGF 165 b enhances an underappreciated VEGFR1 activation to promote previously unknown VEGFR1-STAT3 signaling in ischemic muscle and increases perfusion recovery.
Although extensive literature exists on VEGFR2 signaling networks in PAD, 7, 32 information on VEGFR1 activation and downstream signaling events is sparse. Several of the VEGFR1 functions that have been identified are in nonECs, [33] [34] [35] [36] [37] [38] and endothelium-specific VEGFR1 functions remain uncertain. Our experimental data showed that VEGF 165 b inhibition induces VEGFR1 activation and not VEGFR2 activation or its downstream signaling in Balb/c ischemic muscle. Failure to upregulate VEGFR1 resulted in a loss of this effect. Our in vitro experiments with VEGF 165 a and VEGF 165 b ligand treatments in time-and dose-dependent manner showed that VEGF 165 b has the ability to induce VEGFR2 Y1175 phosphorylation almost to a similar extent as VEGF 165 a in endothelial cells. However, although VEGF 165 a significantly induced VEGFR1 Y1333 activation, VEGF 165 b failed to induce VEGFR1 Y1333 activation in ECs. Consistent with our in vitro experimental findings, VEGF 165 b delivery into nonischemic muscle also decreased endothelium-specific VEGFR1 Y1333 activation but not VEGFR2 Y1175 activation.
Kawamura et al 16 has demonstrated that pulmonary arterial endothelial cells that express VEGFR2 (pulmonary arterial endothelial VEGFR2) or VEGFR2-NRP1 (PAE-VEGFR2-NRP1) treated with VEGF 165 b show increased VEGFR2 activation (Y1052/Y1057) compared with untreated controls but not to the extent induced by VEGF 165 a. 16 Another report by Catena et al 39 demonstrated that recombinant human VEGF 165 b-PP (produced in Pichia Pastoris) was able to induce VEGFR2 Y1175 phosphorylation even more than that of VEGF 165 a, and recombinant human VEGF 165 b-HS (produced in Chinese Hamster Ovarian cells) was able to induce VEGFR2 Y1175 to the same extent as VEGF 165 a in HUVECs. 39 In our current study, we show that VEGF 165 b functions as a blocker of VEGF 165 a-mediated VEGFR1 Y1333 activation (in HEK293-VR1 cells, Figure 4B ) and VEGF165b VEGF 165 b-induced VEGFR2 Y1175 activation (in HEK293-VR2 cells, Figure 4D) We, for the first time, show that activation of VEGFR1 Y1333 is involved in STAT3 activation in ischemic muscle. However, interestingly, we observed that STAT3 activation occurred without any changes in key STAT3 activation kinases, Jak1/ Jak2). Recent report by Lee et al 30 has shown that VEGFR1 is physically associated with STAT3 in cancer cells, and another report by Zhao et al 31 has shown VEGF-A drives breast and lung cancer stem cells self-renewal by increasing VEGFR2/ Jak/STAT3 interactions. VEGFR1 pull-down assays clearly showed that VEGF 165 b inhibition can increase the binding of VEGFR1 to STAT3 resulting in increased STAT3 activation. We further confirmed that VEGFR1 has the ability to regulate STAT3 activation in VEGFR1 +/− mice (on Balb/c background) in ischemic muscle. Our experiments conclude that VEGFR1 binding to STAT3 can increase STAT3 activation post VEGF 165 b inhibition, indicating that a novel VEGFR1-STAT3 signaling is activated in ischemic muscle to promote perfusion recovery. However, the potential mechanisms that regulate VEGFR1-STAT3 interactions to induce STAT3 activation need to be further investigated. One possibility is that the kinase activity of VEGFR1 is responsible for STAT3 activation, and additional binding and adaptor molecules might also be involved in mediating VEGFR1-STAT3 interactions. STAT3 activation can result in the induction of several STAT3 gene targets that have well-documented functions 43, 44 in inhibiting apoptosis and inducing angiogenesis to revascularize ischemic muscle. Our data do not exclude that VEGFR2 activation is important to promote angiogenesis in ischemic muscle in PAD but rather demonstrate that VEGFR1 activation and the resulting STAT3 activation also play a key role in improving perfusion recovery. 45 Our study was largely, but not exclusively, based on data obtained from the use of antibody-mediated approach to inhibit VEGF 165 Figure VIIIA) . Separate from the antibody data, we also confirmed that VEGF 165 bexpressing plasmid delivery (gain of function) decreases VEGFR1 activation, which is consistent with increased VEGFR1 activation with VEGF 165 b antibody treatment (loss of function). These data strongly suggest that the outcomes observed by VEGF 165 b antibody are specific rather than nonspecific events induced by antibody.
Conclusions
VEGFR2 is widely regarded as the dominant VEGF receptor in postnatal/ischemia-mediated angiogenesis. However, our data in both mouse and human PAD showed an inverse correlation between VEGF 165 b binding to VEGFR1, and VEGFR1 activation and depletion of VEGF 165 b from ischemic muscle activates VEGFR1-STAT3 signaling to promote perfusion. Importantly, in addition to increased endothelial VEGFR1-STAT3 activation, increased VEGFR1-STAT3 activation in nonendothelial sources including monocyte/macrophages could also contribute to increased VEGFR1-STAT3 signaling in ischemic muscle. Data from VEGFR1 +/− PAD mice that are unable to upregulate VEGFR1 in ischemic muscle not only confirmed that VEGFR1 plays important role in perfusion but also confirmed that VEGF 165 b modulates VEGFR1 to decrease therapeutic angiogenesis and perfusion in PAD. Our data provide evidence to the theoretical hypothesis that removal of an angiogenesis inhibitor by monoclonal antibody approach may be a superior strategy than delivery of an angiogenic activator to treat ischemic cardiovascular diseases especially PAD.
